Engflag

Carbutol

Quick links to important sections

Carbutol

Carbutol_EN

Method of action: Antianginal, Antiarrhythmic, Antihypertensive, Beta Blocking Agents, Hypotensive

Treatment option: Arrhythmia, Hypertension, Angina Pectoris, Tachycardia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carbutol

Quick Facts about Carbutol

Property Description
Active Ingredient Carbamazepine
Form Oral tablets or extended-release capsules
Pharmacological Class Anticonvulsant / Specific Analgesic
Common Use Management of specific types of nerve pain
Origin Synthetic (lab-made)

What Type of Medicine is Carbutol?

Carbutol is classified as a synthetic, non-opioid pharmaceutical agent primarily used to manage specific types of discomfort associated with nerve activity. This compound, which contains the active ingredient Carbamazepine, is considered a specific analgesic and an anticonvulsant, belonging to the dibenzazepine class of medicines. It is clinically recognized for its targeted action against conditions like trigeminal neuralgia, distinguishing it from conventional, general-purpose pain relievers. As a Prescription Only Medicine (POM), its targeted use reflects the necessity for professional oversight.

Is Carbutol Synthetic, and What is its Composition?

Carbutol is a purely synthetic compound, meaning it is manufactured in a laboratory setting to ensure precise purity and quality, and is not derived from natural plant or animal sources. The medication is available in various oral forms, including standard and extended-release tablets or capsules, designed for systemic absorption via the oral route of administration. The chemical details of Carbamazepine are established, confirming its lab-synthesized origin and structure. This synthesis ensures a consistent, measurable potency tailored for its specialized therapeutic effect.

What is the General Purpose of Carbutol?

The general purpose of Carbutol is to stabilize and calm overactive nerves, thus helping to relieve discomfort and regulate nerve-related symptoms. Pharmacological data supports its effectiveness in managing chronic conditions where nerve signals are erratic or excessive, such as certain types of nerve pain. The active component is recognized for its role in global symptomatic management. This action is designed to restore stability to nerve function, supporting the patient's ability to conduct daily activities without intense, debilitating nerve discomfort.

Regulatory References

  1. Carbatrol Extended-Release Capsules - NIH DailyMed
  2. Carbamazepine on the WHO Essential Medicines List (eEML)

What side effects are possible with Carbutol?

Possible Side Effects and Safety Information

The safety profile of Carbutol, which contains Carbamazepine, is detailed in regulatory documents by classifying potential effects based on their frequency and the physiological systems affected. These classifications reflect how government authorities organize and communicate the medicine’s risk profile, ranging from common, expected effects to rare, serious adverse reactions.

Frequency of Adverse Reactions

Classification Examples of Reactions
Very Common (ge 1/10) Dizziness, somnolence (drowsiness), ataxia (loss of coordination), and leukopenia (decreased white blood cells).
Rare/Very Rare (< 1/1,000) Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Documented Serious Safety Concerns

Regulatory labeling explicitly highlights the risk of life-threatening blood disorders, such as agranulocytosis and aplastic anaemia, which involve severe decreases in necessary blood cell counts. The potential for hepatic failure (severe liver impairment) is also documented. For patients of certain Asian ancestry possessing the *HLA-B1502 genetic marker**, the risk of developing SJS/TEN is significantly elevated according to official safety notes.

Contextual Safety Patterns

The official documentation notes that neurological adverse effects (e.g., dizziness and somnolence) are more frequently observed at the initiation of treatment or during dose increases. The product is officially contraindicated in patients with a history of bone marrow depression or known sensitivity to the drug. Due to documented risks, regulatory agencies require baseline and periodic monitoring of both hematological and hepatic function during the course of therapy.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

Classification Official Regulatory Statements
Documented Overdose Presentations Overdose may present with central nervous system (CNS) depression (e.g., somnolence, disorientation, coma), neuromuscular signs (e.g., nystagmus, ataxia), and cardiovascular effects (e.g., tachycardia, hypotension, and conduction disorders).
Physiological Systems Affected Central Nervous System, Cardiovascular System, Respiratory System, Neuromuscular System, and Fluid and Electrolyte Balance.
Dose-Related Factors Severity is typically dose-related, with significant overexposure associated with severe cardiovascular complications, deep coma, and seizures.
Population-Specific Notes Convulsions or seizures are noted to occur especially in small children following an overdose.
Emergency-Response Admission to a hospital is required, and management is primarily supportive.
Immediate Medical Help Immediate medical attention must be sought for any suspected overdose due to the risk of severe outcomes like profound CNS depression, cardiac arrhythmias, shock, and respiratory compromise.

Overdose Classifications (High-level)

Classification Official Regulatory Statements
Severity Classification Instances ranging from mild CNS effects to life-threatening outcomes, including cardiac arrest and rhabdomyolysis, have been documented.
Antidote Status No specific antidote is known; therefore, management must be symptomatic and supportive.

Resulting Overdose Structure

Official overdose statements:

  • Continuous cardiac monitoring and careful correction of electrolyte imbalance are required procedures.
  • Documented supportive measures include evacuation of the stomach and the administration of activated charcoal.
  • Severe cases may require supportive medical care in an intensive care unit (ICU) and specialized procedures such as extracorporeal treatment.

Connection to the overall overdose profile:

Government regulatory documents define the overdose profile by listing the expected symptom clusters, which are primarily focused on CNS depression and severe cardiotoxicity. Given the formally stated lack of a specific antidote, the regulatory guidance mandates that immediate medical attention must be sought for any suspected overexposure, requiring prompt hospital admission for continuous cardiac monitoring and supportive medical care to sustain vital functions.

Therapeutic Uses of Carbutol

Carbutol is used to help manage certain types of seizure disorders, which may include partial seizures and generalized tonic-clonic seizures. The medication's primary therapeutic goal is to help reduce the frequency of these seizures for individuals with epilepsy, supporting the maintenance of daily activities and overall quality of life. Carbutol also serves to provide relief from the sharp, shooting discomfort of trigeminal neuralgia, a specific type of nerve pain in the face, by assisting in the management of these intense pain episodes. Furthermore, it may be prescribed to support the stability of mood in individuals with bipolar I disorder, particularly during acute manic or mixed mood phases.

Quick Fact: Relief for Trigeminal Neuralgia

Carbutol may help lessen the severity and occurrence of the sudden, intense facial pain associated with trigeminal neuralgia.

Eligibility and Restrictions for Use

Who can and cannot use Carbutol (Modeled on Carbamazepine)?

Official regulatory sources specify multiple conditions and states where the use of Carbutol is either prohibited (contraindicated) or requires special caution.

Contraindicated Populations

Carbutol must not be used in patients with:

  • A history of bone marrow depression (e.g., agranulocytosis or aplastic anemia).
  • Known hypersensitivity or allergy to Carbutol or any compound in the tricyclic antidepressant class (such as amitriptyline or imipramine).
  • Concomitant use with a Monoamine Oxidase Inhibitor (MAOI); MAOIs must be discontinued for a minimum of 14 days before starting Carbutol.

Restrictions and Special Consideration

Use of Carbutol is not recommended or requires enhanced monitoring for the following groups:

  • Pregnancy and Lactation: Use during pregnancy is not recommended unless the clinical benefit clearly outweighs the fetal risk. The drug is present in breast milk, and a decision must be made to either stop nursing or discontinue the medication.
  • Genetic Risk: Patients with Asian ancestry should be screened for the *HLA-B1502** genetic allele prior to initiation, as a positive result significantly increases the risk of severe skin reactions (Stevens-Johnson syndrome/Toxic Epidermal Necrolysis).
  • Hepatic or Renal Impairment: Patients with existing liver or kidney dysfunction require caution and close monitoring. Severe impairment, if defined in the label, may be an absolute contraindication.
  • Cardiac Conditions: Caution is required in patients with pre-existing heart disease, including a history of AV block.
  • Pediatric Use: Safety and efficacy are not established for children under certain age cutoffs for some formulations.
  • Mixed Seizure Disorders: Use is restricted for mixed seizure disorders that include absence seizures due to the potential for seizure exacerbation.

What should I know about interactions with other medicines?

Carbutol has a high potential for clinically significant interactions, primarily because it is a strong inducer of the liver enzyme CYP3A4, as well as other enzymes and transporters like UGT and P-glycoprotein. This induction can significantly decrease the blood levels and therapeutic effects of many co-administered medicines that are substrates of these enzymes, including hormonal contraceptives, certain antiviral medications (e.g., protease inhibitors), and other antiepileptic drugs.

Conversely, drugs that are potent CYP3A4 inhibitors can significantly increase the blood levels of Carbutol, raising the risk of dose-related toxicity. Due to metabolic risks, Carbutol is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs), requiring a minimum 14-day washout period after stopping the MAOI. It is also contraindicated for use with Nefazodone.

Patients should avoid the consumption of grapefruit or grapefruit juice while taking Carbutol, as this can increase the drug's concentration in the body and potentiate adverse effects. Due to the high interaction potential, therapeutic drug monitoring and dose adjustments for both Carbutol and co-administered medicines may be necessary during combination therapy. Furthermore, the medicine is known to autoinduce its own metabolism, a process that stabilizes after approximately three to five weeks of continuous treatment.

Mechanism of Action

Voltage-Gated Sodium Channel Modulation

Carbutol functions as an allosteric modulator that targets voltage-gated sodium channels ( Na v) on neuronal membranes. Its primary action is use-dependent, meaning it preferentially binds to and stabilizes the inactivated state of the channel during periods of high-frequency neuronal firing. This binding prolongs the channel's absolute refractory period, reducing its availability to open and conduct sodium ions ( Na^+).

Dampening Cellular Hyperexcitability

This molecular interaction results in a functional limit on neuronal discharge. By inhibiting the rapid recovery of the Na v channels, the drug imposes a ceiling on the rate at which nerve impulses can be propagated. This mechanism contributes to the stabilization of hyperexcitable nerve membranes and results in a state of decreased electrical excitability within neural circuits by inhibiting high-frequency, synchronous neuronal activity within the affected pathways.

Dosage and Administration Information

Instructions for Use and Dosing Regimen

Carbutol is administered by the oral route (tablets, chewable tablets, suspension, extended-release capsules/tablets) or as a temporary intravenous (IV) infusion.

Official Administration Guidelines

Administration Scope Instructions
Route of Administration Oral or Intravenous (IV) for temporary replacement.
Dosing Schedule Initial dose must be gradually increased (titrated) over several weeks to reach the minimum effective level. Adult initial oral dosing is typically 200 mg twice daily.
Timing in Relation to Meals Immediate-release formulations should be taken with meals to minimize gastrointestinal discomfort. Extended-release capsules may be taken with or without food, but grapefruit and grapefruit juice must be avoided.
Preparation Requirements Oral suspension must be shaken well before each use. Extended-release tablets must be swallowed whole; do not crush, chew, or break them. Extended-release capsules may be swallowed whole or the contents sprinkled over a teaspoon of soft food (e.g., applesauce) and swallowed immediately.
Age-Group Rules Dosing for children younger than 12 years is weight-based, typically starting at 10 to 20 mg/kg/day in divided doses. The maximum daily dose for children aged 12 to 15 is 1000 mg, and 1200 mg for patients over 15 years of age.
Missed-Dose Rules If a dose is missed, take it as soon as it is remembered unless it is nearly time for the next scheduled dose. In this case, skip the missed dose and resume the regular schedule. Do not take two doses at the same time.
Special Procedural Conditions Prior to initiation, monoamine oxidase (MAO) inhibitors must be discontinued for a minimum of 14 days. IV administration for replacement therapy is calculated as 70% of the patient’s total daily oral dose, divided into four equal 30-minute infusions separated by 6 hours.

Recent Clinical Evidence

Carbutol (Modeled on Carbamazepine): Recent Clinical Evidence

Evidence for Carbutol

Carbutol is a commonly evaluated substance. Its properties and function were explored in relation to certain inflammatory pathways and cellular receptors.

Studies reviewed the subject tolerability of this substance in various patient groups. Research assessed its outcomes on the rate of symptom onset in acute scenarios. Investigators assessed changes in the severity of symptoms in relevant studies.

Key Research Areas

  • Symptom Outcomes: Research explored whether it was associated with changes in reported discomfort. Separately, changes in pain levels were examined in a double-blind, randomized trial. Findings varied between different subgroups analyzed.

  • Tolerability Profile: Research included assessments of side effect reporting and subject tolerability in pediatric and geriatric populations. One large-scale observational study also examined long-term adverse event reporting and the durability of any observed effects.

  • Comparison Studies: Multiple trials examined the substance's measured outcomes. These were compared to a placebo and a standard-of-care compound. The body of evidence is limited regarding establishing comparative outcomes.

Combination Therapies: Carbutol + Substance Y

Studies investigated the relationship between the combination of Carbutol and Substance Y and overall symptomatic outcomes. Research explored whether the combination was associated with differences in adverse event reporting rates when compared to monotherapy with Carbutol alone.

Note: This text strictly describes the scope and findings of the research reviewed; it does not offer clinical interpretation or advice.

Key Studies & References

  1. Carbamazepine: Systematic review of efficacy and safety in trigeminal neuralgia

Frequently Asked Questions (FAQ)

Common questions about Carbutol (Modeled on Carbamazepine) (FAQ)

Q: When is the best time to take Carbutol?

Carbutol is commonly recommended to be taken at bedtime. This is often based on the product label and how the medication is processed by the body.

Always follow the dosing instructions provided by a healthcare professional, as they may be customized for your specific health needs.

Q: Can I stop taking Carbutol once my condition is normal?

Carbutol is typically prescribed as a long-term treatment to manage a condition and reduce risk. Stopping Carbutol suddenly may lead to a return of symptoms.

It is important to consult your doctor or healthcare provider before stopping the medication or making any changes to your prescribed dose.

Q: What should I do if I miss a dose of Carbutol?

If a dose of Carbutol is missed, patients are generally advised to take it as soon as they remember.

However, if it is close to the time for the next scheduled dose, the product information usually recommends skipping the missed dose and continuing with the regular schedule. Never take two doses to make up for a single missed dose.

Always refer to the patient information leaflet or discuss with a pharmacist for precise instructions on a missed dose, as the specific time window for taking a missed dose may vary.

How should Carbutol be stored and disposed of?

How to Store and Dispose of Carbutol

Official regulatory guidelines dictate specific conditions for storing and disposing of Carbutol to maintain its stability and ensure safety.

Storage and Stability

Carbutol must be stored at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F), and protected from moisture and excessive heat. It is a mandatory requirement to keep the medication in its original, tightly closed container and store it out of the sight and reach of children.

For the liquid oral suspension, the product must not be frozen and any unused portion must be discarded 4 months after the initial opening.

Disposal Instructions

Unused or expired Carbutol should be disposed of through a regulatory-approved method, such as a drug take-back program or secure household trash disposal (mixed with an undesirable substance in a sealed container). Regulatory documents explicitly instruct users not to dispose of the medication via wastewater (sinks or toilets).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTunisia

Equivalent of Carbutol found in:

A-Z Index: